Intellia Therapeutics Inc’s recent filing unveils that its EVP, Chief Scientific Officer Schultes Birgit C unloaded Company’s shares for reported $539.0 on Oct 01 ’25. In the deal valued at $17.38 per share,31 shares were sold. As a result of this transaction, Schultes Birgit C now holds 105,184 shares worth roughly $1.47 million.
Then, Dube Michael P sold 1,871 shares, generating $32,518 in total proceeds. Upon selling the shares at $17.38, the VP, Chief Accounting Officer now owns 55,266 shares.
Before that, CHASE WILLIAM J bought 100,000 shares. Intellia Therapeutics Inc shares valued at $1,003,000 were divested by the Director at a price of $10.03 per share. As a result of the transaction, CHASE WILLIAM J now holds 134,693 shares, worth roughly $1.88 million.
RBC Capital Mkts downgraded its Intellia Therapeutics Inc [NTLA] rating to a Sector perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Bernstein’s analysts, who decreased its forecast for the stock in late October from “an Outperform” to “a Mkt perform”. William Blair also remained covering NTLA and has decreased its forecast on October 27, 2025 with a “Mkt perform” recommendation from previously “an Outperform” rating. Guggenheim revised its rating on October 27, 2025. It rated NTLA as “a Neutral” which previously was an “a Buy”.
Price Performance Review of NTLA
On Tuesday, Intellia Therapeutics Inc [NASDAQ:NTLA] saw its stock fall -5.61% to $13.96. Over the last five days, the stock has lost -48.24%. Intellia Therapeutics Inc shares have fallen nearly -11.92% since the year began. Nevertheless, the stocks have risen 19.73% over the past one year. While a 52-week high of $28.25 was reached on 10/20/25, a 52-week low of $5.90 was recorded on 04/07/25.
Levels Of Support And Resistance For NTLA Stock
The 24-hour chart illustrates a support level at 13.52, which if violated will result in even more drops to 13.09. On the upside, there is a resistance level at 14.59. A further resistance level may holdings at 15.23.
How much short interest is there in Intellia Therapeutics Inc?
A steep rise in short interest was recorded in Intellia Therapeutics Inc stocks on 2025-10-15, dropping by -3.23 million shares to a total of 30.9 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 34.14 million shares. There was a decline of -10.46%, which implies that there is a negative sentiment for the stock.
